On August 6, 2021, the U.S. Food and Drug Administration (FDA) released final guidance regarding near-infrared (NIR) analytical procedures. The guidance applies to new drug applications (NDAs), abbreviated new drug applications (ANDAs), and supplemental NDAs and ANDAs for small-molecule drugs. The FDA will address recommendations for NIR methods used in biologics under a future revision of the guidance.
The new guidance provides the agency’s recommendations for the development, validation, and use of NIR-based analytical procedures in evaluating a drug product’s identity, strength, quality, purity, and potency. The recommendations address the application of concepts described in FDA and International Council for Harmonization guidelines to NIR analytical procedures that use chemometric models. It also discusses submitting NIR documentation in applications.
The guidance does not discuss the development and validation of NIR analytical procedures or the setup, qualification, maintenance, or calibration of NIR instruments. The concepts of the guidance can be applied to other analytical technologies.
An Interview with AES Mid-Career Award Recipient Jason Dwyer
July 25th 2024Jason Dwyer of the University of Rhode Island has been named the recipient of the American Electrophoresis Society’s Mid-Career Award, which honors exceptional contributions to the field of electrophoresis, microfluidics, and related areas by an individual who is currently in the middle of their career.
Glucose's Impact on Brain Cancer Cells Unveiled Through Raman Imaging
July 25th 2024Researchers have used Raman spectroscopy and chemometric methods to reveal how glucose affects normal and cancerous brain cell metabolism. Their findings highlight specific biomarkers that can distinguish metabolic changes, potentially aiding in cancer research and treatment.